Investigation Into Capricor Therapeutics Sparks Concerns
Pomerantz LLP is initiating an investigation on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm seeks to determine if the company and its executives engaged in fraudulent activities or other unlawful business practices that may have impacted stockholder value.
Understanding the Company's Situation
Recent developments involving Capricor have raised red flags among investors. The firm announced that after completing a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application for deramiocel, an experimental cell therapy aimed at treating Duchenne muscular dystrophy (DMD) cardiomyopathy, the FDA indicated it would convene an advisory committee meeting.
Market Reaction to FDA Communications
After the FDA's communication, Capricor's stock experienced a significant decline, dropping $3.00, or 29.13%, with shares closing at $7.30. Such dramatic fluctuations highlight investor skepticism surrounding the efficacy and future of Capricor's therapies.
Further Complications Arise
The situation worsened when an industry publication reported that the head of the FDA unit overseeing Capricor had canceled the advisory committee meeting. This cancellation stemmed from unresolved concerns regarding the efficacy and safety of deramiocel, leading to a further plummet in Capricor's stock price by $3.68, or 30.82%, closing at $8.26.
About Pomerantz LLP
Pomerantz LLC has a longstanding reputation in corporate, securities, and antitrust class action litigation. Established over 85 years ago by Abraham L. Pomerantz, who is celebrated for his extensive contributions to securities class actions, the firm remains committed to advocating for those harmed by securities fraud and corporate misconduct. Their notable history includes successfully retrieving multimillion-dollar settlements for numerous affected clients.
What Investors Should Do
Investors of Capricor are encouraged to closely follow updates on the situation and consider their legal options. If any questionable actions are discovered involving Capricor or its executives, there may be pathways to seek justice and compensation for losses incurred.
Contact Information for Interested Parties
For further inquiries, investors can reach out to Danielle Peyton from Pomerantz LLP via phone at 646-581-9980, ext. 7980. It is essential for affected investors to stay informed and take necessary action promptly.
Frequently Asked Questions
What triggered the investigation into Capricor Therapeutics?
The investigation was initiated due to concerns over potential fraud or unlawful practices by the company, particularly following significant stock price declines.
How did Capricor's stock price react to recent FDA announcements?
Capricor’s stock dropped notably, with a decline of 29.13% after the initial FDA communication and another 30.82% following the cancellation of the advisory committee meeting.
What is deramiocel?
Deramiocel is an investigational cell therapy aimed at treating Duchenne muscular dystrophy cardiomyopathy. It is currently under review by the FDA.
Who is Pomerantz LLP?
Pomerantz LLP is a prominent law firm specializing in corporate and securities class actions, dedicated to advocating for victims of securities fraud and corporate misconduct.
How can investors participate in the investigation?
Investors interested in joining the investigation can contact Pomerantz LLP for more information regarding their rights and potential claims.
